fda compounding glp-1 crackdown news today The is drawing a harder line on compounded weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA enforcement The FDA is cracking down

Administration and Safety TB-500 Administration: Commonly given via subcutaneous injection Typically used in 46 week cycles Initial phase: 23 injections per week Maintenance phase: Reduced frequency as directed by a healthcare provider BPC-157 Administration: Can be taken via subcutaneous injection, localized injection, or oral capsule (for gut health) Dosage varies depending on injury type and severity Can be used for short-term injury recovery or longer cycles for chronic conditions Safety Note: Both TB-500 and BPC-157 should be used under medical supervision

Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies)

Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes

The industry can also benefit from aging populations, rising healthcare spending, and demand for treatments that is relatively resilient across economic cycles

Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria